Xcout IntelSilence Therapeutics Plc
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Subscribe to see Silence Therapeutics Plc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Silence Therapeutics Plc at a glance
Silence Therapeutics Plc is a biotech company headquartered in London, United Kingdom, founded in 1994. It is publicly listed (SLN) with a market capitalisation of $545.6M. Xcout tracks 16 named people at Silence Therapeutics Plc, including Iain Gladstone Ross (Interim CEO & Chairman of the Board).
Silence Therapeutics Plc leadership
- Iain Gladstone RossInterim CEO & Chairman of the Board
- Rhonda L. HellumsExecutive VP, CFO, Secretary & Executive Director
- Steven J. RomanoExecutive Vice President and Chief Research & Development Officer
- Curtis RambaranChief Medical Officer
- GabrielChief Technical Operations Officer
- Marie Wikstrom LindholmChief Scientific Officer
10 more named people on record for Silence Therapeutics Plc, with roles, board committees and tenure — see the full roster →
Silence Therapeutics Plc competitors
A few of Silence Therapeutics Plc's closest competitors — see the full list of competitors and alternatives →
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Nosis Biosciences develops receptor-targeted RNA medicines utilizing its proprietary AI-powered platform, Connexa, which combines physics-aware deep learning, single cell biology, and high-throughput chemistry. The company's platform designs gene-silencing therapeutics intended to treat chronic conditions across various cell types and organ systems, including the heart, lungs, kidneys, and brain.
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Skip Therapeutics is an Israeli biotechnology company founded in 2021 and based in Ness Ziona. The company develops personalized RNA-based therapies, including antisense oligonucleotides, for rare genetic disorders and common diseases using a proprietary computational discovery engine.
Circio Holding ASA is a biotechnology company that develops novel circular RNA and immunotherapy medicines, utilizing its proprietary circVec platform to enhance gene therapy for genetic diseases. It serves the biopharmaceutical sector and patients with genetic disorders by advancing clinical programs and engaging in research collaborations.
Get Silence Therapeutics Plc's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Silence Therapeutics Plc in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access